PRESS RELEASE
Q2 2025 — Press release
Q2 2025PDF · 15 pages840 KB
E A R N I N G S R E L E A S E
ELEVANCE HEALTH REPORTS SECOND QUARTER 2025 RESULTS
• 2Q 2025 operating revenue of $49.4 billion, up 14.3% from 2Q 2024
• 2Q 2025 diluted EPS1 of $7.72; adjusted diluted EPS2 of $8.84
• Revising FY 2025 adjusted diluted EPS guidance to approximately $30.00
• Returned $2.0 billion of capital to shareholders year-to-date
Indianapolis, IN - July 17, 2025 - Elevance Health, Inc. (NYSE: ELV) reported second
quarter 2025 results.
"In the second quarter, Elevance Health made meaningful progress in delivering an experience
that is simple and personal to those we serve, while advancing our efforts to enhance efficiency
across the healthcare system. We are updating our outlook to reflect elevated medical cost
trends in ACA and slower rate alignment in Medicaid. While the external environment
continues to evolve, we are focused on the areas within our control - managing healthcare
costs, deploying targeted investments in advanced technology and value-based care delivery,
and reinforcing the operational foundation that supports long-term value creation. With the
embedded earnings power of our diversified Health Benefits and Carelon businesses, we
remain confident in achieving at least 12% average annual growth in adjusted diluted EPS over
time."
Gail K. Boudreaux
President and Chief Executive Officer
Given the ongoing and industry-wide impact of elevated cost trends in ACA and Medicaid,
Elevance Health now expects 2025 GAAP net income per diluted share to be approximately
$24.10 and adjusted net income per diluted share to be approximately $30.00.
1. Earnings per diluted share ("EPS").
2. Refer to GAAP reconciliation tables on pages 13 and 14 herein for reconciliation of GAAP to adjusted measures.
1
-- 1 of 15 --
Elevance Health
Consolidated Enterprise Highlights
(Unaudited)
(In billions) Three Months Ended
June 30, 2025 June 30, 2024
Operating Revenue1 $49.4 $43.2
Operating Gain1,2 $2.4 $2.8
Adjusted Operating Gain1,3 $2.5 $2.9
Operating Margin1 4.9 % 6.4 %
Adjusted Operating Margin1,3 5.0 % 6.7 %
1. See “Basis of Presentation” on page 5 herein.
2. Operating Gain for the three months ended June 30, 2025, and June 30, 2024, include items that are excluded from adjusted shareholders' net
income. See "GAAP Reconciliation" on pages 13 and 14 herein.
3. Adjusted Operating Gain for the three months ended June 30, 2025, and June 30, 2024, exclude items that are excluded from adjusted
shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
Operating revenue was $49.4 billion in the second quarter of 2025, an increase of $6.2 billion, or 14
percent compared to the prior year quarter. This was driven by higher premium yields in our Health
Benefits segment, recently closed acquisitions, and growth in our Medicare Advantage membership,
partially offset by membership attrition in our Medicaid business.
The benefit expense ratio was 88.9 percent, an increase of 260 basis points year over year, reflecting
higher medical cost trend primarily in our Medicaid business and ACA health plans. Days in Claims
Payable stood at 43.9 days as of June 30, 2025, when adjusted for our acquisition of CareBridge. This
represents a decrease of 0.1 days sequentially on a comparable basis.
The operating expense ratio was 10.1 percent, an improvement of 160 basis points. The adjusted
operating expense ratio was 10.0 percent, an improvement of 140 basis points, primarily driven by
expense leverage associated with growth in operating revenue and ongoing expense discipline as we
prioritize investments to support our long-term strategy.
Cash Flow & Balance Sheet
Operating cash flow was $3.1 billion year-to-date, or 0.8 times GAAP net income, an increase of $0.6
billion year over year. As of June 30, 2025, cash and investments at the parent company totaled
approximately $2.2 billion.
During the second quarter of 2025, the Company repurchased 0.9 million shares of its common stock for
$379 million, at a weighted average price of $410.05, and paid a quarterly dividend of $1.71 per share,
representing a distribution of cash totaling $385 million. As of June 30, 2025, the Company had
approximately $8.0 billion of Board approved share repurchase authorization remaining.
2
-- 2 of 15 --
Health Benefits is comprised of Individual, Employer Group risk-based, Employer Group fee-based,
BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses.
Health Benefits
Reportable Segment Highlights
(Unaudited)
(In billions) Three Months Ended
June 30, 2025 June 30, 2024
Operating Revenue1 $41.6 $37.2
Operating Gain1,2 $1.6 $2.1
Adjusted Operating Gain1,3 $1.6 $2.2
Operating Margin1 3.8 % 5.8 %
Adjusted Operating Margin1 3.8 % 5.8 %
1. See “Basis of Presentation” on page 5 herein.
2. Operating Gain for the three months ended June 30, 2024, includes items that are excluded from adjusted shareholders' net income. See "GAAP
Reconciliation" on pages 13 and 14 herein.
3. Adjusted Operating Gain for the three months ended June 30, 2024, excludes $15 million of 2024 business dispositions and related items adjusted
out of adjusted shareholders' net income for the Health Benefits segment.
Health Benefits segment operating revenue was $41.6 billion in the second quarter of 2025, an increase
of $4.4 billion, or 12 percent compared to the prior year quarter, driven primarily by higher premium
yields, recently closed acquisitions, and growth in our Medicare Advantage membership, partially offset
by lower Medicaid membership.
Operating gain totaled $1.6 billion, impacted principally by higher medical cost trend in our Medicaid
business and ACA health plans.
Medical membership totaled approximately 45.6 million as of June 30, 2025, a decline of 212 thousand
from the first quarter of 2025, driven by lower Medicaid membership and attrition resulting from lower
effectuation rates in our Individual ACA business.
3
-- 3 of 15 --
Carelon is comprised of CarelonRx and Carelon Services.
Carelon
Reportable Segment Highlights
(Unaudited)
(In billions) Three Months Ended
June 30, 2025 June 30, 2024
Operating Revenue1,2 $18.1 $13.3
Operating Gain1,3 $0.9 $0.7
Adjusted Operating Gain1,4 $0.9 $0.7
Operating Margin1 5.2 % 5.3 %
Adjusted Operating Margin1 5.2 % 5.6 %
1. See “Basis of Presentation” on page 5 herein.
2. Operating Revenue for the three months ended June 30, 2024, includes $0.2 billion of revenue related to 2024 business dispositions and related
items that have been excluded from adjusted operating gain.
3. Operating Gain for the three months ended June 30, 2024, includes items that are excluded from adjusted shareholders' net income. See "GAAP
Reconciliation" on pages 13 and 14 herein.
4. Adjusted Operating Gain for the three months ended June 30, 2024, excludes $44 million of 2024 business dispositions and related items adjusted
out of adjusted shareholders' net income for the Carelon segment.
Operating revenue for Carelon was $18.1 billion in the second quarter of 2025, an increase of $4.8
billion, or 36 percent compared to the prior year quarter. This was driven by recent acquisitions in home
health and pharmacy services, growth in CarelonRx product revenue, and the scaling of innovative risk-
based capabilities in Carelon Services.
Operating gain for Carelon totaled $0.9 billion, an increase of $0.2 billion, or 33 percent, primarily
driven by improved Carelon Health performance and higher CarelonRx product revenue.
4
-- 4 of 15 --
Quarterly Dividend
On July 16, 2025, the Audit Committee of the Company's Board of Directors declared a third quarter
2025 dividend to shareholders of $1.71 per share. The third quarter dividend is payable on September
25, 2025, to shareholders of record at the close of business on September 10, 2025.
About Elevance Health
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity.
The company supports consumers, families, and communities across the entire healthcare journey –
connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s
companies serve over 109 million consumers through a diverse portfolio of industry-leading medical,
pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please
visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.
Conference Call and Webcast
Management will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time (“EDT”)
to discuss the company’s second quarter results and outlook. The conference call should be accessed at
least 15 minutes prior to the start of the call with the following numbers:
888-947-9963 (Domestic) 866-511-1890 (Domestic Replay)
312-470-0178 (International) 203-369-1945 (International Replay)
The access code for today's conference call is 3972058. There is no access code for the replay. The
replay will be available from 11:30 a.m. EDT today, until the end of the day on August 15, 2025. The
call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link.
A webcast replay will be available following the call.
Basis of Presentation
1. Operating revenue and operating gain/loss are the key measures used by management to evaluate
performance in each of its reporting segments, allocate resources, set incentive compensation
targets and to forecast future operating performance. Operating gain/loss is calculated as total
operating revenue less benefit expense, cost of products sold and operating expense. It does not
include net investment income, net gains/losses on financial instruments, interest expense,
amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as
these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Refer to pages 13 and 14 for the GAAP reconciliation tables.
2. Operating margin is defined as operating gain divided by operating revenue.
Elevance Health Contacts:
Investor Relations Media
Nathan Rich Leslie Porras
Investor.Relations@elevancehealth.com Leslie.Porras@elevancehealth.com
5
-- 5 of 15 --
Elevance Health
Earnings Release Financial Schedules and Supplementary Information
Quarter & Year-to-Date Ended June 30, 2025
• Membership and Other Metrics
• Quarterly & Year-to-Date Consolidated Statements of Income
• Condensed Consolidated Balance Sheet
• Condensed Consolidated Statement of Cash Flows
• Supplemental Financial Information - Reportable Segments
• Supplemental Financial Information - Reconciliation of Medical Claims Payable
• Reconciliation of Non-GAAP Financial Measures
6
-- 6 of 15 --
Elevance Health
Membership and Other Metrics
(Unaudited)
Change from
Medical Membership (in thousands) June 30,
2025 June 30,
2024 March 31,
2025 June 30,
2024 March 31,
2025
Individual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,348 1,281 1,423 5.2 % (5.3) %
Employer Group Risk-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,615 3,648 3,638 (0.9) % (0.6) %
Commercial Risk-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,963 4,929 5,061 0.7 % (1.9) %
BlueCard® . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,570 6,692 6,608 (1.8) % (0.6) %
Employer Group Fee-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20,584 20,542 20,522 0.2 % 0.3 %
Commercial Fee-Based . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27,154 27,234 27,130 (0.3) % 0.1 %
Medicare Advantage . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,255 2,031 2,255 11.0 % — %
Medicare Supplement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 874 894 876 (2.2) % (0.2) %
Total Medicare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,129 2,925 3,131 7.0 % (0.1) %
Medicaid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8,733 9,028 8,862 (3.3) % (1.5) %
Federal Employee Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,642 1,660 1,649 (1.1) % (0.4) %
Total Medical Membership . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45,621 45,776 45,833 (0.3) % (0.5) %
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts . . . . . . . . . . . . . . . . . . . . . . . . . . . 83.3 78.2 83.9 6.5 % (0.7) %
Carelon Services Consumers Served . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97.3 102.3 99.5 (4.9) % (2.2) %
7
-- 7 of 15 --
Elevance Health
Consolidated Statements of Income
(Unaudited)
(In millions, except per share data)
Three Months Ended
June 30
Six Months Ended
June 30
2025 2024 Change 2025 2024 Change
Revenues
Premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 41,271 $ 35,416 16.5 % $ 82,158 $ 71,112 15.5 %
Product revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,042 5,530 9.3 % 11,851 10,029 18.2 %
Service fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,108 2,277 (7.4) % 4,177 4,355 (4.1) %
Total operating revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49,421 43,223 14.3 % 98,186 85,496 14.8 %
Net investment income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 486 508 (4.3) % 1,076 973 10.6 %
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (131) (85) NM (595) (246) NM
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 240 NM — 240 NM
Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49,776 43,886 13.4 % 98,667 86,463 14.1 %
Expenses
Benefit expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36,706 30,572 20.1 % 72,018 61,118 17.8 %
Cost of products sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,293 4,820 9.8 % 10,276 8,645 18.9 %
Operating expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,997 5,066 (1.4) % 10,297 9,952 3.5 %
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341 280 21.8 % 685 545 25.7 %
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 162 (9.3) % 302 278 8.6 %
Total expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47,484 40,900 16.1 % 93,578 80,538 16.2 %
Income before income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,292 2,986 (23.2) % 5,089 5,925 (14.1) %
Income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 548 685 (20.0) % 1,161 1,375 (15.6) %
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,744 2,301 (24.2) % 3,928 4,550 (13.7) %
Net income attributable to noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1) (1) NM (2) (4) NM
Shareholders' net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1,743 $ 2,300 (24.2) % $ 3,926 $ 4,546 (13.6) %
Shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 7.72 $ 9.85 (21.6) % $ 17.33 $ 19.44 (10.9) %
Diluted shares . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225.8 233.4 (3.3) % 226.5 233.8 (3.1) %
Benefit expense as a percentage of premiums . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88.9 % 86.3 % 260 bp 87.7 % 85.9 % 180 bp
Operating expense as a percentage of total operating revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.1 % 11.7 % (160) bp 10.5 % 11.6 % (110) bp
Income before income tax expense as a percentage of total revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.6 % 6.8 % (220) bp 5.2 % 6.9 % (170) bp
"NM" = calculation not meaningful
8
-- 8 of 15 --
Elevance Health
Condensed Consolidated Balance Sheet
(In millions)
June 30,
2025 December 31,
2024
Assets (Unaudited)
Current assets:
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $8,560 $8,288
Fixed maturity and equity securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26,232 26,393
Premium and other receivables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23,125 19,071
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,407 4,700
Assets held for sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 490
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63,324 58,942
Long-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11,553 10,784
Property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4,641 4,652
Goodwill and other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39,858 40,371
Other noncurrent assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,562 2,140
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $121,938 $116,889
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $17,155 $15,746
Short-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 360 365
Current portion of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,648 1,649
Other current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24,671 22,668
Liabilities held for sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 153
Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43,834 40,581
Long-term debt, less current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28,178 29,218
Other noncurrent liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6,075 5,664
Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78,087 75,463
Total shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43,722 41,315
Noncontrolling interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 111
Total equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43,851 41,426
Total liabilities and equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $121,938 $116,889
9
-- 9 of 15 --
Elevance Health
Condensed Consolidated Statement of Cash Flows
(Unaudited)
(In millions) Six Months Ended June 30
2025 2024
Operating activities
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $3,928 $4,550
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 753 666
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162 154
Changes in operating assets and liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (2,003) (2,943)
Other non-cash items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231 (2)
Net cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,071 2,425
Investing activities
Proceeds from (purchases of) investments, net of sales and maturities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 329 (1,415)
Purchases of subsidiaries, net of cash acquired/sold . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 (725)
Purchases of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (463) (602)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (504) (386)
Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (584) (3,128)
Financing activities
Net change in short-term and long-term borrowings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,255) 2,580
Repurchase and retirement of common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (1,258) (1,029)
Cash dividends . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (771) (757)
Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,067 (94)
Net cash (used in) provided by financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (2,217) 700
Effect of foreign exchange rates on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (5)
Change in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272 (8)
Cash and cash equivalents at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8,288 6,526
Cash and equivalents included in assets held for sale at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — (21)
Cash and cash equivalents at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $8,560 $6,497
10
-- 10 of 15 --
REPORTABLE SEGMENTS
Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal
Employee Program businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as
well as corporate expenses not allocated to our other reportable segments).
Elevance Health
Reportable Segment Highlight Details
(Unaudited)
(In millions) Three Months Ended June 30 Six Months Ended June 30
2025 2024 Change 2025 2024 Change
Operating Revenue
Health Benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $41,582 $37,159 11.9 % $83,013 $74,417 11.6 %
CarelonRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10,643 8,774 21.3 % 20,759 16,841 23.3 %
Carelon Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7,441 4,545 63.7 % 13,977 8,554 63.4 %
Corporate & Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232 122 90.2 % 397 249 59.4 %
Eliminations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (10,477) (7,377) NM5 (19,960) (14,565) NM5
Total Operating Revenue1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $49,421 $43,223 14.3 % $98,186 $85,496 14.8 %
Operating Gain (Loss)
Health Benefits2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $1,560 $2,145 (27.3) % $3,777 $4,432 (14.8) %
CarelonRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 536 497 7.8 % 1,138 1,020 11.6 %
Carelon Services2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400 208 92.3 % 891 498 78.9 %
Corporate & Other2,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (71) (85) NM5 (211) (169) NM5
Total Operating Gain1,4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $2,425 $2,765 (12.3) % $5,595 $5,781 (3.2) %
Operating Margin
Health Benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.8 % 5.8 % (200) bp 4.5 % 6.0 % (150) bp
CarelonRx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.0 % 5.7 % (70) bp 5.5 % 6.1 % (60) bp
Carelon Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5.4 % 4.6 % 80 bp 6.4 % 5.8 % 60 bp
Total Operating Margin1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.9 % 6.4 % (150) bp 5.7 % 6.8 % (110) bp
1. See “Basis of Presentation” on page 5 herein.
2. Operating Gain for the three and six months ended June 30, 2024, included $59 and $119 million, respectively, of 2024 business dispositions and related items; including $44 and $88 million, respectively, for the Carelon Services segment; and $15 and $31 million, respectively, for the
Health Benefits segment. Operating Gain for the three and six months ended June 30, 2024, included $64 and $116 million, respectively, of transaction and integration related costs, $9 and $11 million, respectively, of litigation and settlement expenses, and $4 and $0 million,
respectively, of business optimization charges, all of which reside in the Corporate & Other reportable segment.
3. Operating Gain for the three and six months ended June 30, 2025, included $53 and $133 million, respectively, of transaction and integration related costs and $10 and $15 million, respectively, of litigation and settlement expenses, which reside in the Corporate & Other reportable
segment.
4. Operating Gain for the three and six months ended June 30, 2025, and June 30, 2024, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on pages 13 and 14 herein.
5. "NM" = calculation not meaningful.
11
-- 11 of 15 --
Elevance Health
Reconciliation of Medical Claims Payable
Six Months Ended June 30 Years Ended December 31
2025 2024 2024 2023 2022
(In millions) (Unaudited) (Unaudited)
Gross medical claims payable, beginning of period $ 15,580 $ 15,865 $ 15,865 $ 15,348 $ 13,282
Ceded medical claims payable, beginning of period (13) (7) (7) (6) (21)
Net medical claims payable, beginning of period 15,567 15,858 15,858 15,342 13,261
Business combinations and purchase adjustments 182 — 143 — 133
Net incurred medical claims:
Current year 71,090 60,551 125,370 121,798 113,414
Prior years redundancies1
(1,065) (1,473) (1,731) (1,571) (869)
Total net incurred medical claims 70,025 59,078 123,639 120,227 112,545
Net payments attributable to:
Current year medical claims 57,117 48,297 110,930 107,146 98,997
Prior years medical claims 11,802 11,584 13,143 12,565 11,600
Total net payments 68,919 59,881 124,073 119,711 110,597
Net medical claims payable, end of period 16,855 15,055 15,567 15,858 15,342
Ceded medical claims payable, end of period 16 12 13 7 6
Gross medical claims payable, end of period2
$ 16,871 $ 15,067 $ 15,580 $ 15,865 $ 15,348
Current year medical claims paid as a percentage of current year net incurred medical claims 80.3 % 79.8 % 88.5 % 88.0 % 87.3 %
Prior year redundancies in the current year as a percentage of prior year net medical claims
payable less prior year redundancies in the current year 7.3 % 10.2 % 12.3 % 11.4 % 7.0 %
Prior year redundancies in the current year as a percentage of prior year net incurred medical
claims 0.9 % 1.3 % 1.4 % 1.4 % 0.9 %
1. Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated.
2. Excludes insurance lines other than short duration.
12
-- 12 of 15 --
Elevance Health
GAAP Reconciliation
(Unaudited)
This document references non-GAAP measures, including “Adjusted Shareholders’ Net Income,” “Adjusted Shareholders’ Net Income Per Share,” “Adjusted EPS,” “Adjusted Operating Gain,” “Adjusted Operating Expense”
and “Adjusted Operating Expense Ratio,” which are non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to
be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available below. In
addition to these non-GAAP measures, references are made to the measures “Operating Revenue” and “Operating Gain/Loss,” “Operating Margin” and “Adjusted EPS”. Operating revenue and operating gain/loss are the key
measures used by management to evaluate performance in each of its reportable segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated
as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other
intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Each of
these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated
Statements of Income herein. A reconciliation of the non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP, together with a reconciliation of reportable segments operating gain
to income before income tax expense, is provided below. Prior amounts may be grouped differently to conform to the current presentation. Net adjustment items per share may not sum due to rounding. A reconciliation of
Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein.
Three Months Ended
June 30 Six Months Ended
June 30
(In millions, except per share data) 2025 2024 Change 2025 2024 Change
Shareholders' net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1,743 $ 2,300 (24.2) % $ 3,926 $ 4,546 (13.6) %
Add / (Subtract):
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 162 302 278
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131 85 595 246
Transaction and integration related costs1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 64 133 116
Litigation and settlement expenses1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 9 15 11
Business dispositions and related items2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 59 — 119
Business optimization charges1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 4 — —
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — (240) — (240)
Tax impact of non-GAAP adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (87) (38) (255) (134)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254 105 790 396
Adjusted shareholders' net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1,997 $ 2,405 (17.0) % $ 4,716 $ 4,942 (4.6) %
Shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 7.72 $ 9.85 (21.6) % $ 17.33 $ 19.44 (10.9) %
Add / (Subtract):
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.65 0.69 1.33 1.19
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.58 0.36 2.63 1.05
Transaction and integration related costs1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.23 0.27 0.59 0.50
Litigation and settlement expenses1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.04 0.04 0.07 0.05
Business dispositions and related items2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 0.25 — 0.51
Business optimization charges1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 0.02 — —
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — (1.03) — (1.03)
Tax impact of non-GAAP adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (0.39) (0.16) (1.13) (0.57)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.12 0.45 3.49 1.70
Adjusted shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 8.84 $ 10.30 (14.2) % $ 20.82 $ 21.14 (1.5) %
Three Months Ended
June 30 Six Months Ended
June 30
(In millions) 2025 2024 Change 2025 2024 Change
Income before income tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 2,292 $ 2,986 (23.2) % $ 5,089 $ 5,925 (14.1) %
Net investment income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (486) (508) (1,076) (973)
Gain on sale of business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — (240) — (240)
Net losses on financial instruments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131 85 595 246
Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 341 280 685 545
Amortization of other intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 162 302 278
Reportable segments operating gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 2,425 $ 2,765 (12.3) % $ 5,595 $ 5,781 (3.2) %
1. Adjustment item resides in the Corporate & Other reportable segment.
2. Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
13
-- 13 of 15 --
Elevance Health
GAAP Reconciliation
(Unaudited)
Three Months Ended
June 30 Six Months Ended
June 30
(In millions) 2025 2024 Change 2025 2024 Change
Reportable segments operating gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 2,425 $ 2,765 (12.3) % $ 5,595 $ 5,781 (3.2) %
Add / (Subtract):
Transaction and integration related costs1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 64 133 116
Litigation and settlement expenses1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 9 15 11
Business dispositions and related items2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 59 — 119
Business optimization charges1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — 4 — —
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 136 148 246
Reportable segments adjusted operating gain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 2,488 $ 2,901 (14.2) % $ 5,743 $ 6,027 (4.7) %
Three Months Ended
June 30 Six Months Ended
June 30
(In millions) 2025 2024 Change 2025 2024 Change
Operating expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4,997 $ 5,066 (1.4) % $ 10,297 $ 9,952 3.5 %
Add / (Subtract):
Transaction and integration related costs1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (53) (64) (133) (116)
Litigation and settlement expenses1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (10) (9) (15) (11)
Business dispositions and related items2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — (59) — (119)
Business optimization charges1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . — (4) — —
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (63) (136) (148) (246)
Adjusted operating expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 4,934 $ 4,930 0.1 % $ 10,149 $ 9,706 4.6 %
Operating revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 49,421 $ 43,223 14.3 % $ 98,186 $ 85,496 14.8 %
Operating expense ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.1 % 11.7 % (160) bp 10.5 % 11.6 % (110) bp
Adjusted operating expense ratio . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10.0 % 11.4 % (140) bp 10.3 % 11.4 % (110) bp
Full Year
2025 Outlook
Shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Approximately $24.10
Add / (Subtract):
Net losses on financial instruments3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $3.28
Amortization of other intangible assets3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $2.98
Transaction and integration related costs1,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $1.35
Litigation and settlement expenses1,3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $0.10
Tax impact of non-GAAP adjustments3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Approximately ($1.81)
Net adjustment items . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $5.90
Adjusted shareholders' earnings per diluted share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Approximately $30.00
1. Adjustment item resides in the Corporate & Other reportable segment.
2. Adjustment item resides in the Health Benefits and Carelon Services reportable segments.
3. Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount.
14
-- 14 of 15 --
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,”
“feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify
forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions;
statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future
performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control,
that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are
cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully
review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from
time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update
or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include,
but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium
rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new
or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy
services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security
incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related
thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial
intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market
conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to
changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid
programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve
improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue
received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government
investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing
healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance
by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity related to
the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible
impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions
in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our
common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential
negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact
our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses
with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international
operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.
15
-- 15 of 15 --